

STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease

NCT07280585

Status	RECRUITING
Phase	Phase 3
Sponsor	University of Cologne
Enrollment	420 participants

Key Eligibility Criteria

Inclusion (9)

- Male and female patients with ADPKD (modified Ravine criteria) e 18 and d 60 years
- Patients 18 - 39 years: eGFR e25 ml/min; patients 40 - 60 years: eGFR e25 and \<90 ml/min/1.73 m2
- Indicators of rapid progression, either of the following:
- Mayo class 1D-E
- Mayo class 1C AND EITHER

... and 4 more (see full listing online)

Exclusion (13)

- Treatment with tolvaptan, somatostatin analogue, lithium or SGLT2i within the last 3 months before screening
- Medical history of diabetic ketoacidosis, necrotizing fasciitis or organ transplantation
- Diabetes mellitus type 1 or any type of diabetes mellitus due to insulin deficiency
- Uncontrolled ongoing urinary tract or genital infections
- Known intolerance of the study medication ingredients

... and 8 more (see full listing online)

Locations (27 total)

Vorarlberger Krankenhaus-Betriebsgesellschaft, Feldkirch, Austria
Medizinische Universitaet Innsbruck, Innsbruck, Austria
Universitaetsklinikum Aachen AöR, Aachen, Germany

... and 24 more locations